Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

Treading new ground There is no FDA-approved therapy for peanut allergy in the one to three age group, although in 2020 the regulator cleared Aimmune Therapeutics’ oral immunotherapy Palforzia ...

The global food allergy market is experiencing remarkable growth, projected to reach a valuation of USD 66.15 Billion by the end of 2033, expanding at a CAGR of 5.2% from its estimated value of USD 39 ...

Claim your 7-day free trial now. Summit Therapeutics Inc SMMT stock is trading lower on Friday. On Thursday, Summit Therapeutics’ partner Akeso Inc. received the U.S. Food and Drug ...

Poster presentation on Monday, June 2, 2025 from 1:30 - 4:30 PM CDT at the ASCO Annual Meeting MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea” or the ...

The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. 2 Stocks That Have More Than Doubled in the ...

Viking Therapeutics Inc (NASDAQ:VKTX) announced positive data from four separate clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis. The company made significant ...

The catalyst for the 36% price decline on Friday was Akeso announcing the NMPA approval of ivonescimab in China for the treatment of PD-L1 positive NSCLC patients with new overall survival (OS ...

Also Read: FDA Lifts Clinical Hold On vTv Therapeutics’ Phase 3 Diabetes Trial, Stock Surges To date, no serious adverse events have been observed in subjects enrolled in the Phase 1b study.

Mosaic Therapeutics, Ltd ('Mosaic') a targeted oncology therapeutics company dedicated to resolving cancer's complexity with new combination therapies for patients, today announces the in ...

The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. 2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade 3 ...

In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a ...